Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Elevidys
Elevidys
Roche reports positive topline outcomes from DMD treatment trial
Clinical Trials Arena
Tue, 01/28/25 - 10:24 am
Roche
Elevidys
DMD
gene therapy
clinical trials
Sanofi sues Sarepta, claiming Duchenne gene therapy Elevidys infringes 2 manufacturing patents
Fierce Pharma
Tue, 07/30/24 - 06:35 pm
Sarepta Therapeutics
Sanofi
legal
patents
Elevidys
DMD
After full approval, Sarepta lays out its next moves
BioSpace
Wed, 06/26/24 - 11:31 am
Sarepta Therapeutics
DMD
Elevidys
gene therapy
Sarepta Duchenne gene therapy wins broader use from FDA
BioPharma Dive
Thu, 06/20/24 - 06:09 pm
Sarepta Therapeutics
gene therapy
FDA
DMD
Elevidys
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive
Thu, 06/13/24 - 11:07 pm
Pfizer
DMD
gene therapy
FDA
Sarepta Therapeutics
Elevidys
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
BioSpace
Wed, 05/8/24 - 11:13 am
Sarepta Therapeutics
DMD
Elevidys
gene therapy
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
BioPharma Dive
Thu, 03/7/24 - 11:05 am
Regenxbio
Duchenne Muscular Dystrophy
DMD
RGX-202
Sarepta Therapeutics
Elevidys
Sarepta’s Duchenne Gene Therapy Elevidys Nabs $200M on Strong Demand
BioSpace
Thu, 02/29/24 - 11:00 am
Sarepta Therapeutics
gene therapy
Elevidys
earnings
Duchenne Muscular Dystrophy
FDA to review Sarepta's Duchenne gene therapy for traditional approval
Reuters
Fri, 02/16/24 - 11:38 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Elevidys
Sarepta's next DMD drug seems to get the job done, but Elevidys casts long shadow
Fierce Biotech
Mon, 01/29/24 - 10:25 pm
Sarepta Therapeutics
DMD
SRP-5051
Elevidys
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
Motley Fool
Mon, 01/22/24 - 10:13 pm
Sarepta Therapeutics
Elevidys
Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion
Fierce Pharma
Thu, 11/2/23 - 05:15 pm
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
Elevidys
gene therapy
Sarepta gene therapy for Duchenne misses main goal of key study
BioPharma Dive
Mon, 10/30/23 - 08:17 pm
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
clinical trials
FDA
Elevidys
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Sarepta offers early look at closely watched gene therapy launch
BioPharma Dive
Thu, 08/3/23 - 11:19 am
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Elevidys
drug launches
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Sarepta prices Duchenne gene therapy at $3.2M
BioPharma Dive
Fri, 06/23/23 - 09:44 am
Sarepta Therapeutics
drug pricing
DMD
Duchenne Muscular Dystrophy
Elevidys
FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
BioSpace
Thu, 06/22/23 - 10:51 pm
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
FDA
Elevidys
gene therapy